Literature DB >> 17872839

Should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? NO.

Shawn D Aaron1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17872839      PMCID： PMC1949246     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  9 in total

1.  Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.

Authors:  Shelley R Salpeter; Nicholas S Buckley; Edwin E Salpeter
Journal:  J Gen Intern Med       Date:  2006-10       Impact factor: 5.128

Review 2.  Short-acting beta 2 agonists for stable COPD.

Authors:  P Sestini; E Renzoni; S Robinson; P Poole; F S Ram
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 3.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

Review 4.  Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.

Authors:  S Appleton; P Poole; B Smith; A Veale; T J Lasserson; M M Chan
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

5.  Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease.

Authors:  D E O'Donnell; S M Revill; K A Webb
Journal:  Am J Respir Crit Care Med       Date:  2001-09-01       Impact factor: 21.405

6.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.

Authors:  Peter Calverley; Romain Pauwels; Jørgen Vestbo; Paul Jones; Neil Pride; Amund Gulsvik; Julie Anderson; Claire Maden
Journal:  Lancet       Date:  2003-02-08       Impact factor: 79.321

7.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Authors:  Peter M A Calverley; Julie A Anderson; Bartolome Celli; Gary T Ferguson; Christine Jenkins; Paul W Jones; Julie C Yates; Jørgen Vestbo
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

Review 8.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease--2003.

Authors:  Denis E O'Donnell; Shawn Aaron; Jean Bourbeau; Paul Hernandez; Darcy Marciniuk; Meyer Balter; Gordon Ford; Andre Gervais; Roger Goldstein; Rick Hodder; Francois Maltais; Jeremy Road
Journal:  Can Respir J       Date:  2003 May-Jun       Impact factor: 2.409

9.  Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease.

Authors:  D E O'Donnell; N Voduc; M Fitzpatrick; K A Webb
Journal:  Eur Respir J       Date:  2004-07       Impact factor: 16.671
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.